Cell Therapeutics, Inc. and Systems Medicine, LLC , a wholly-owned subsidiary of CTI, announced that preclinical data presented at the 19th annual AACR-NCI-EORTC Symposium show an antibody to IGF-II may solve the problems of low blood sugar associated with drug candidates working through insulin receptor-linked pathways.
Read More...
[Source: Yahoo! News Search Results for testicular cancer]
Thursday, October 25, 2007
Novel Alternative Approach to Inhibiting Insulin Growth Factor (IGF) May Provide New Treatment for Breast Cancer and ... (PR Newswire via Yahoo! Finance)
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment